A biotechnology company focused on developing monoclonal antibody therapies for migraine and other neurological disorders. Its lead asset, eptinezumab, targets the calcitonin gene-related peptide (CGRP) pathway and was developed as a preventive treatment for chronic and episodic migraine. Investors ...
3 members of Congress have disclosed 8 trades in Alder BioPharmaceuticals Inc (ALDR), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-03-07 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2015-10-06 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2015-09-10 | Kurt Schrader | buy | $1K – $15K |
| 2015-08-19 | Kurt Schrader | buy | $1K – $15K |
| 2015-08-18 | Kurt Schrader | buy | $1K – $15K |
| 2015-08-08 | Kurt Schrader | buy | $1K – $15K |
| 2015-02-13 | Thomas MacArthur | buy | $1K – $15K |
| 2015-02-02 | Thomas MacArthur | buy | $1K – $15K |